FE 999326

· Ferring Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FE 999326, covering 2025-08-28 to 2025-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 3]

See pricing